The clinical importance of fibroblast growth factor 23 on advanced non-small cell lung cancer patients without druggable alterations in genes as EGFR or ALK or ROS1 Fibroblast growth factor 23
Serdar Arici1, Ruhper Cekin2, Saban Secmeler2, Muhammed Mustafa Atci2, Birol Ocak3, Abdullah Sakin4, Sener Cihan51Department of Medical Oncology, Istanbul Okmeydani Training and Research Hospital,Istanbul,Turkey, 2Department of Medical Oncology, Istanbul Okmeydani Training and Research Hospital,Istanbul,T, 3Department of Medical Oncology, Faculity of Medicine, Uludag University, Bursa, Turkey, 4Department of Medical Oncology, Faculity of Medicine, Yuzuncu Yil University, Van, Turkey, 5Medical Oncology Department, Istanbul Okmeydani Training and Research Hospital,Istanbul,Turkey
Objectives: We aimed to investigate the relation between serum fibroblast growth factor (FGF) 23 levels and clinicopathologic features of stage 3B and 4 non-small cell lung cancer (NSCLC) patients without druggable alterations in genes as epidermal growth factor receptor (EGFR) or rearrangements of the anaplastic lymphoma kinase (ALK) or c-ROS oncogene 1 (ROS1), by comparing healthy control group. Methods: This was a prospective, single-center study. Newly diagnosed stage 3B and 4 NSCLC patients without druggable alterations in genes as EGFR, ALK or ROS1 and healthy control in similar age, without any chronic disease and vitamin D deficiency were enrolled in the study. Fibroblast growth factor 23 levels were compared between groups. Results: Forty men newly diagnosed stage 3B and 4 patients and 24 healthy men were enrolled. The median age of patients and controls were 54.7 and 53.1 years. The number of patients were 22 (55.0%) and 18 (45.0%) in stage 3B and stage 4 groups respectively. The mean FGF 23 level was calculated as 87.7±58.0 pg/ml in patients group and 63.1±11.4 pg/ml in control group (p=0.045). Fibroblast growth factor 23 levels were 85.5±42.5 pg/ml and 89.6±69.1 in metastatic and non-metastatic patients respectively (p=0.532). The median FGF 23 levels were 91.1±58.4 pg/ml and 92.5±60.8 pg/ ml in squamous cell carcinoma and adenocarcinoma groups respectively (p=0.926). Conclusion: Our study suggests that high FGF-FGFR interaction may be causative for stage 3B and 4 NSCLC without druggable alterations in genes as EGFR, ALK or ROS1 and is important in terms of suggesting the FGF pathway as a new treatment target in NSCLC patients. Keywords: Druggable alterations, fibroblast growth factor 23, non-small cell lung cancer
Cite This Article
Arici S, Cekin R, Secmeler S, Atci M, Ocak B, Sakin A, Cihan S. The clinical importance of fibroblast growth factor 23 on advanced non-small cell lung cancer patients without druggable alterations in genes as EGFR or ALK or ROS1 Fibroblast growth factor 23. EJMI. 2020; 4(3): 365-369
Corresponding Author: Serdar Arici